MGB
FULC icon

Mass General Brigham’s Fulcrum Therapeutics FULC Stock Holding History

Mass General Brigham’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$733K Hold
205,356
– – 1.68% 5
2024
Q2 		$1.27M Hold
205,356
– – 6.2% 4
2024
Q1 		$1.94M Buy
+205,356
New +$1.83M 3.39% 5
2021
Q4 		– Sell
-15,860
Closed -$447K – 8
2021
Q3 		$447K Buy
+15,860
New +$301K 0.12% 7

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mass General Brigham's FULC Position: Q3 2024 in Review

Mass General Brigham held its Fulcrum Therapeutics (FULC) position steady in Q3 2024 at 205,356 shares worth $733K. The position accounts for 1.68% of the portfolio, ranked #5.

Mass General Brigham first reported a position in FULC in Q3 2021 and has held it in 4 quarters since. The position peaked at $1.94M in Q1 2024. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

  • Mass General Brigham held 205,356 shares of Fulcrum Therapeutics worth $733K as of Q3 2024.
  • Mass General Brigham left its Fulcrum Therapeutics share count unchanged in Q3 2024.
  • Fulcrum Therapeutics made up 1.68% of Mass General Brigham's portfolio in Q3 2024, its #5 holding.
  • Mass General Brigham first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • Mass General Brigham's Fulcrum Therapeutics position peaked at $1.94M in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on Mass General Brigham's 13F filing for Q3 2024, filed 16 Oct 2024.